Today it was reported that the SVP & GC of Enanta Pharmaceuticals (NASDAQ: ENTA), Nathaniel Gardiner, exercised options to buy 1,500 ENTA shares at $34.70 a share, for a total transaction value of $52.05K.
This recent transaction increases Nathaniel Gardiner’s holding in the company by 12.17% to a total of $1.16 million. Following Nathaniel Gardiner’s last ENTA Buy transaction on February 12, 2018, the stock climbed by 7.4%.
See today’s analyst top recommended stocks >>
ENTA’s market cap is $1.63B and the company has a P/E ratio of 20.87. Currently, Enanta Pharmaceuticals has an average volume of 596.6K.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $110.00, reflecting a 40.6% upside.
The insider sentiment on Enanta Pharmaceuticals has been positive according to 27 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Nathaniel Gardiner’s trades have generated a 12.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It offers the two protease inhibitors Maviret and the Viekira Pak for the treatment of chronic hepatitis C virus.
